Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

医学 放射治疗 化疗 神经母细胞瘤 肿瘤科 危险系数 原发性肿瘤 内科学 多元分析 转移 核医学 泌尿科 置信区间 癌症 遗传学 生物 细胞培养
作者
Dana L. Casey,Kenneth L. Pitter,Brian H. Kushner,Nai‐Kong V. Cheung,Shakeel Modak,Michael P. LaQuaglia,Suzanne L. Wolden
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:100 (5): 1204-1209 被引量:22
标识
DOI:10.1016/j.ijrobp.2018.01.008
摘要

Purpose

As part of consolidative therapy in high-risk neuroblastoma, modern protocols recommend radiation therapy (RT) both to the primary site and to sites of metastatic disease that persist after induction chemotherapy. Although there are abundant data showing excellent local control (LC) with 21 Gy directed at the primary site, there are few data describing the feasibility and efficacy of RT directed at metastatic sites of disease as part of consolidation.

Methods and Materials

All patients with neuroblastoma who received RT to metastatic sites of disease as a part of consolidative therapy at a single institution between 2000 and 2015 were reviewed. Among 159 patients, 244 metastases were irradiated.

Results

The median follow-up period among surviving patients was 7.4 years. Over 85% of the irradiated metastases were treated with 21 Gy (range, 10.5-36 Gy). Tumor recurrence occurred in 43 of 244 irradiated metastases (18%). The 5-year LC rate of treated metastatic sites was 81%. Metastatic sites that cleared with induction chemotherapy had improved LC compared with sites with persistent uptake on metaiodobenzylguanidine scans (LC rate, 92% vs 67%; P < .0001). LC at irradiated metastatic sites did not differ based on total number of sites irradiated or site of disease irradiated (bone vs soft tissue). Patients with bulky, resistant disease who were treated with 30 to 36 Gy had worse LC (P = .02). However, on multivariate analysis, only persistence after induction chemotherapy remained a significant prognostic factor for LC (hazard ratio, 3.7; P < .0001). Patients who had LC at irradiated metastatic sites had improved overall survival compared with those who did not (overall survival rate, 71% vs 50%; P < .0001).

Conclusions

Response to chemotherapy is an important prognostic factor for LC at irradiated metastatic sites in neuroblastoma. Overall, consolidative RT appears to be an effective modality of LC. Long-term disease control can be achieved with such an approach.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cc完成签到,获得积分10
1秒前
赵怼怼完成签到,获得积分10
2秒前
无奈的豆沙包完成签到 ,获得积分10
2秒前
逢春完成签到,获得积分10
3秒前
十二完成签到,获得积分10
5秒前
123完成签到,获得积分10
5秒前
6秒前
单纯的小土豆完成签到,获得积分10
6秒前
白枫完成签到 ,获得积分10
6秒前
明亮乘风发布了新的文献求助10
6秒前
彪壮的幻丝完成签到 ,获得积分10
6秒前
6秒前
晴天完成签到,获得积分20
7秒前
熙梓日记完成签到,获得积分10
7秒前
縤雨完成签到 ,获得积分10
8秒前
ZhouYW完成签到,获得积分0
9秒前
雾雨礁发布了新的文献求助10
10秒前
qqdm完成签到 ,获得积分10
12秒前
TheSilencer完成签到 ,获得积分10
13秒前
聂青枫完成签到,获得积分10
16秒前
顾矜应助一盏壶采纳,获得10
16秒前
19秒前
迅速天空完成签到 ,获得积分10
19秒前
wss完成签到,获得积分20
19秒前
TCB完成签到,获得积分10
19秒前
激流勇进wb完成签到 ,获得积分10
19秒前
十八完成签到 ,获得积分10
20秒前
我是大皇帝完成签到 ,获得积分10
22秒前
zxm完成签到,获得积分10
23秒前
气急败坏的卡尔王完成签到 ,获得积分10
23秒前
研友_5Zl9D8完成签到,获得积分10
23秒前
赘婿应助外套waitlen采纳,获得10
25秒前
makeincraze发布了新的文献求助10
25秒前
水薄荷完成签到,获得积分10
26秒前
28秒前
BOLIN完成签到,获得积分10
28秒前
努力向上的小刘完成签到,获得积分10
32秒前
蓝胖子完成签到 ,获得积分10
32秒前
高木同学完成签到,获得积分10
33秒前
有魅力小刺猬完成签到 ,获得积分10
33秒前
高分求助中
Technologies supporting mass customization of apparel: A pilot project 600
Izeltabart tapatansine - AdisInsight 500
Chinesen in Europa – Europäer in China: Journalisten, Spione, Studenten 500
Arthur Ewert: A Life for the Comintern 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi // Kurt Werner Radtke 500
Two Years in Peking 1965-1966: Book 1: Living and Teaching in Mao's China // Reginald Hunt 500
Epigenetic Drug Discovery 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3815941
求助须知:如何正确求助?哪些是违规求助? 3359417
关于积分的说明 10402560
捐赠科研通 3077261
什么是DOI,文献DOI怎么找? 1690255
邀请新用户注册赠送积分活动 813693
科研通“疑难数据库(出版商)”最低求助积分说明 767743